E-selectin is a cell-adhesion molecule of the vascular endothelium that promotes essential leukocyte rolling in the early inflammatory response by binding to glycoproteins containing the tetrasaccharide sialyl Lewisx (sLex). Efficient leukocyte recruitment under vascular flow conditions depends on an increased lifetime of E-selectin/ligand complexes under tensile force in a so-called catch-bond binding mode. Co-crystal structures of a representative fragment of the extracellular E-selectin region with sLex and a glycomimetic antagonist thereof reveal an extended E-selectin conformation, which is identified as a high-affinity binding state of E-selectin by molecular dynamics simulations. Small-angle X-ray scattering experiments demonstrate a direct link between ligand binding and E-selectin conformational transition under static conditions in solution. This permits tracing a series of concerted structural changes connecting ligand binding to conformational stretching as the structural basis of E-selectin catch-bond-mediated leukocyte recruitment. The detailed molecular view of the binding site paves the way for the design of a new generation of selectin antagonists. This is of special interest, since their therapeutic potential was recently demonstrated with the pan-selectin antagonists GMI-1070 (Rivipansel).

By forming extended hydrogen-bond networks, the contribution of hydroxyl groups to affinity can reach several orders of magnitude. However, because of the high directionality of their interactions, a maximal affinity gain can only be achieved when the ligand scaffold allows a perfect spatial fit with the binding site. In contrast to the broad potential of hydroxyl groups for molecular recognition is their exceptionally high desolvation penalty, which can equally reduce binding affinity. As a consequence, alcohols are rarely present in synthetic drugs but predominantly found in therapeutics derived directly or inspired from natural products, which were shaped under evolutionary pressure. In this perspective, advantages as well as drawbacks influencing the use of OH groups in medicinal chemistry are discussed and illustrated with four exemplary case studies. Additionally, guidelines for drug design are derived from common features found in existing therapeutics.

Frequent antibiotic treatment of urinary tract infections has resulted in the emergence of antimicrobial resistance, necessitating alternative treatment options. One such approach centers around FimH antagonists that block the bacterial adhesin FimH, which would otherwise mediate binding of uropathogenic Escherichia coli to the host urothelium to trigger the infection. Although the FimH lectin can adopt three distinct conformations, the evaluation of FimH antagonists has mainly been performed with a truncated construct of FimH locked in one particular conformation. For a successful therapeutic application, however, FimH antagonists should be efficacious against all physiologically relevant conformations. Therefore, FimH constructs with the capacity to adopt various conformations were applied. By examining the binding properties of a series of FimH antagonists in terms of binding affinity and thermodynamics, we demonstrate that depending on the FimH construct, affinities may be overestimated by a constant factor of 2 orders of magnitude. In addition, we report several antagonists with excellent affinities for all FimH conformations.

No abstract

Interacting with lectins, mannose can be mimicked with seven-membered ring analogues but at the price of a substantial entropy penalty.